PALB2 pathogenic variants are reported to be significantly associated with TNBC or HR-negative breast cancer in the unselected breast cancer cohorts (Zhou et al. 2020; Breast Cancer Association Consortium et al. 2022). This evidence concerns the gene PALB2 and breast carcinoma.